Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

No longer available 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1NSCLC 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 8Pemetrexed 8capmatinib 7Carboplatin 7ceritinib 5Cisplatin 5Bevacizumab 4Docetaxel 3trametinib 2motexafin gadolinium 2aldesleukin 2Vinorelbine 2Paclitaxel 2Interleukin-2 2Gefitinib 2BID protein, human 2technetium 99m etarfolatide 1spartalizumab 1sintilimab 1satraplatin 1ribociclib 1picropodophyllin 1nazartinib 1naporafenib 1milademetan 1lazertinib 1fludarabine phosphate 1fludarabine 1farletuzumab 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma of Lung × BID protein, human × Clear all
NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡